Group 1 - The company announced the establishment of a joint venture in China, with the company holding 34% and partners holding 63% [1] - The joint venture received capital injections of HKD 3,400,000 from the company and HKD 6,300,000 from partners, with no further funding commitments expected [1] - The formation of the joint venture aims to leverage resources and expertise for mutual benefits, enhancing operational efficiency and product marketing in the healthcare sector [1] Group 2 - The board has decided to add a new core business segment focused on Superoxide Dismutase (SOD), which has unique scientific mechanisms and advantages in industrialization [2] - SOD is expected to be applicable in high-end medical aesthetics, functional foods, and specialized medical fields, supported by intellectual property barriers and core patents [2] - The introduction of the SOD business segment is anticipated to open new growth avenues in biomedicine and upgrade existing consumer businesses, creating a technology-driven valuation system [2]
帝王国际投资(00928.HK)拟成立合营进一步推动集团医疗保健业务